Printer Friendly

PROCTER & GAMBLE ISSUES STATEMENT CONCERNING NYQUIL

 PROCTER & GAMBLE ISSUES STATEMENT CONCERNING NYQUIL
 CINCINNATI, April 9 /PRNewswire/ -- The Procter & Gamble Company (NYSE: PG) issued the following statement today in response to recent questions about the effectiveness of the antihistamine in its NyQuil Cold Medicine:
 NyQuil has been used safely by millions of cold sufferers for 25 years to effectively relieve cold suffering.
 Sneezing and runny nose -- major symptoms relieved by antihistamines -- are among the top five symptoms people want a cold medicine to work on. Consumer testing shows that NyQuil provides highly satisfying relief of these and other cold symptoms. Millions of NyQuil users know this. That's why we call it: "The nighttime, sniffling, sneezing, coughing, aching, stuffy head, fever, so you can rest medicine."
 One of NyQuil's ingredients, an antihistamine, effectively relieves the "sniffling and sneezing" part of a cold. In fact, that antihistamine was used by doctors for decades on a prescription basis before being approved for use in non-prescription cold medicines.
 Fifteen human clinical studies, conducted over many years, have proven that antihistamines, including the one used in NyQuil, produce relief of sneezing and runny nose for cold sufferers.
 The results of all this research have been reviewed and confirmed by independent scientific experts. Based on the scientific data shared with the U.S. Food and Drug Administration, the FDA has long approved antihistamines as effective in non-prescription cold medicines.
 Beyond effectiveness, there is a large body of scientific evidence showing that antihistamines are safe for use in non-prescription cold medicines. This safety research has included several studies on NyQuil and its antihistamine ingredient alone.
 Questions about the effectiveness of antihistamines in non- prescription cold medicines were raised by several critics of over- the-counter drugs at a U.S. House of Representatives committee hearing on April 8, 1992.
 -0- 4/9/92
 /CONTACT: Donald P. Tassone of Procter & Gamble, 513-983-4271/
 (PG) CO: Procter & Gamble ST: Ohio IN: SU:


KK -- CL014 -- 6861 04/09/92 14:26 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 9, 1992
Words:323
Previous Article:FLEET/NORSTAR, MASS. ATTORNEY GENERAL REACH AGREEMENT ON RESTITUTION/ LOAN PROGRAM, $12 MILLION MORTAGE FUND FOR LOW-INCOME RESIDENTS
Next Article:CINCINNATI/NORTHERN KENTUCKY INTERNATIONAL AIRPORT AND DELTA WORKING TO REDUCE AIRCRAFT NOISE


Related Articles
SUDAFED MANUFACTURER WANTS DAYQUIL TELEVISION ADVERTISEMENTS STOPPED COLD
People Are 'Mad' About Mornings -- One Way or the Other, Says New NyQuil Survey.
Rich Foss Joins Motorola as Vice President and Director of Global Brand Strategy.
Important Statement from Procter & Gamble on PPA Drug Recall.
New Survey Shows Americans Are Sick AND Tired; How much sleep are you losing?
This Season, Sinus Symptoms Have Met Their Match!
Germaphobes Beware: New Survey Uncovers the Dirt on American's Fears and Strange Hygiene Habits.
Happy Days are Here With a Little Help From America's Favorite TV Mom and New Vicks(R) DayQuil/NyQuil Plus Vitamin C(R).
Vicks(R) Has Introduced DayQuil(R) Mucus Control(TM) and DayQuil(R) Mucus Control(TM) DM.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters